Volume 16, Issue 1 (March 2024 2024)                   Iranian Journal of Blood and Cancer 2024, 16(1): 21-34 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Baghdadi H, Shakouri Khomartash M, Ahmadi N, Faridfar A, Ghorbani M. Ikaros (IKZF1): From Normal Hematopoiesis to Hematologic Malignancies. Iranian Journal of Blood and Cancer 2024; 16 (1) :21-34
URL: http://ijbc.ir/article-1-1483-en.html
1- Department of Medical Laboratory Sciences, School of Allied Medical Sciences, AJA University of Medical Sciences, Tehran, 1411718541, Iran
2- Medical Biotechnology Research Center, AJA University of Medical Sciences, Tehran, 1411718541, Iran
3- AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, 1411718541, Iran
4- Department of Medical Laboratory Sciences, School of Allied Medical Sciences, AJA University of Medical Sciences, Tehran, 1411718541, Iran , M.ghorbani@ajaums.ac.ir
Abstract:   (429 Views)
Ikaros zinc finger (IKZF) transcription factors, part of the Krüppel family, have a significant role in the physiological development of immune cells. Ikaros, which is encoded by IKZF1, is a well-researched IKZF transcription factor that specifically impacts the growth and differentiation of lymphocytes. It interacts with various nuclear factors, functioning as either a transcriptional inhibitor or activator; thus, regulates several lymphopoiesis-associated factors like pre-TCR and pre-BCR. Over the years, research has revealed that alterations in IKZF1 as well as Ikaros can cause out-of-control differentiation and proliferation of immune cells, particularly lymphocytes, potentially triggering tumorigenesis in hematologic malignancies such as ALL, AML, CLL, and CML. Recent studies have explored the therapeutic potential of targeting Ikaros or restoring its activities to limit the pathologic differentiation and proliferation of tumor cells. Most of these therapeutic agents are immunomodulatory drugs (IMiDs) that can selectively ubiquitinate and proteasome degrade Ikaros. This study offers a comprehensive overview of Ikaros’s physiological roles and highlights the oncogenic characteristics of IKZF1 and Ikaros alterations.
Full-Text [PDF 696 kb]   (87 Downloads)    
: Review Article | Subject: Genetics
Received: 2023/11/17 | Accepted: 2024/01/26 | Published: 2024/03/25

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb